Literature DB >> 8195706

Role of Fc gamma receptors in cancer and infectious disease.

P K Wallace1, A L Howell, M W Fanger.   

Abstract

Receptors for the Fc domain of immunoglobulin G (Fc gamma R) provide an interface between specific humoral immunity and the cellular branch of the immune system through their interaction with antibody. Cross-linking Fc gamma R on myeloid cells triggers such diverse functions as clearance of immune complexes, phagocytosis of opsonized pathogens, secretion of reactive oxygen intermediates, and antibody-dependent cellular cytotoxicity. The Fc gamma R play a major role in the removal of antibody-coated infectious agents and are the exclusive trigger molecules for tumor cell killing by human myeloid cells. Studies of Fc gamma R function have been aided by the use of Fc gamma R specific monoclonal antibodies, self-directed target cells, and bispecific antibodies that link target cells or pathogens to specific host cell molecules, including Fc gamma R. These reagents have contributed significantly to our understanding of the role of the different classes of Fc gamma R in mediating protection from various infectious agents and in mediating tumor cell killing. Taken together, these approaches have provided insight into the utility of manipulating Fc gamma R function in the therapy of cancer and infectious disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195706     DOI: 10.1002/jlb.55.6.816

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  Cytokine responses of human blood monocytes stimulated with Igs.

Authors:  J L Foreback; D G Remick; E Crockett-Torabi; P A Ward
Journal:  Inflammation       Date:  1997-10       Impact factor: 4.092

2.  Lipopolysaccharide enhances FcgammaR-dependent functions in vivo through CD11b/CD18 up-regulation.

Authors:  C Rubel; P Miliani De Marval; M Vermeulen; M A Isturiz; M S Palermo
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

3.  Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.

Authors:  Z Zhong; L A Pirofski
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

4.  Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.

Authors:  I A Heijnen; M J van Vugt; N A Fanger; R F Graziano; T P de Wit; F M Hofhuis; P M Guyre; P J Capel; J S Verbeek; J G van de Winkel
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

5.  c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.

Authors:  Joseph C Murray; Dalal Aldeghaither; Shangzi Wang; Rochelle E Nasto; Sandra A Jablonski; Yong Tang; Louis M Weiner
Journal:  Cancer Immunol Res       Date:  2014-10-09       Impact factor: 11.151

6.  Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG.

Authors:  Claudia Maletzki; Annika Jahnke; Christiane Ostwald; Ernst Klar; Friedrich Prall; Michael Linnebacher
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

Review 7.  Host factors influencing susceptibility to HIV infection and AIDS progression.

Authors:  Juan Lama; Vicente Planelles
Journal:  Retrovirology       Date:  2007-07-25       Impact factor: 4.602

Review 8.  Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies.

Authors:  Ngoc Phuong Lan Le; Thomas A Bowden; Weston B Struwe; Max Crispin
Journal:  Biochim Biophys Acta       Date:  2016-04-20

Review 9.  FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.

Authors:  Sara Caratelli; Tommaso Sconocchia; Roberto Arriga; Andrea Coppola; Giulia Lanzilli; Davide Lauro; Adriano Venditti; Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurillo; Soldano Ferrone; Giuseppe Sconocchia
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

10.  Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.

Authors:  Emi Harada; Satoshi Serada; Minoru Fujimoto; Yusuke Takahashi; Tsuyoshi Takahashi; Hisashi Hara; Rie Nakatsuka; Takahito Sugase; Takahiko Nishigaki; Yurina Saito; Kosuke Hiramatsu; Satoshi Nojima; Risa Mitsuo; Tomoharu Ohkawara; Eiichi Morii; Masaki Mori; Yuichiro Doki; Yasufumi Kaneda; Tetsuji Naka
Journal:  Oncotarget       Date:  2017-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.